MDT-AP-0366
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 57.96
- os_event
- true
- age_years
- 3
- sex
- F
- new_clusters
- C3
- umap1_2d
- 5.201370776
- umap2_2d
- 3.151569285
- umap1_3d
- 2.505454639
- umap2_3d
- -2.641610422
- umap3_3d
- -2.430948243
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.330
- DNA_REPAIR+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MYC_TARGETS_V1+0.280
- OXIDATIVE_PHOSPHORYLATION+0.280
- PI3K_AKT_MTOR_SIGNALING+0.280
- G2M_CHECKPOINT+0.260
- WNT_BETA_CATENIN_SIGNALING+0.260
- MITOTIC_SPINDLE+0.250
- NOTCH_SIGNALING+0.250
Top 10 suppressed
- BILE_ACID_METABOLISM-0.350
- INTERFERON_ALPHA_RESPONSE-0.310
- HEDGEHOG_SIGNALING-0.270
- COAGULATION-0.210
- KRAS_SIGNALING_DN-0.180
- KRAS_SIGNALING_UP-0.180
- ALLOGRAFT_REJECTION-0.130
- INTERFERON_GAMMA_RESPONSE-0.130
- COMPLEMENT-0.110
- PEROXISOME-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | e255e8fa-b1c7-42bf-9934-4ea44bed860f | — | — | 0.821 |
| 2 | MNG646 | — | — | 0.791 |
| 3 | 58A2E073-D3DE-44B2-9065-3DE14B53B3A2 | — | — | 0.776 |
| 4 | 1F4CD8D0-E2FD-45AA-8CE2-8C0488916778 | — | — | 0.775 |
| 5 | 113340B4-B092-4B8C-8A13-5932525B0C33 | — | — | 0.771 |
| 6 | SRR934938 | — | — | 0.769 |
| 7 | A21DDF04-BECE-498B-81EA-F6953CD30D82 | — | — | 0.751 |
| 8 | MNG437 | — | — | 0.747 |
| 9 | MNG252 | — | — | 0.745 |
| 10 | TCGA-56-A5DR-01A-11R-A27Q-07 | — | cohortSQ1 | 0.745 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |